09
2017-07
2017 Clinical Summit Forum: Where There Is the Market,There Are Clinical Trials | Primary Scene
Dr.Chuangxing Guo of Suzhou Kintor gave a presentation on the implementation of dual declaration of Proxalutamide in China and the United States at the "2017 China Novel Drugs Clinical Development Summit Forum" sponsored by PharmaDJ.Existing data proves that Proxalutamide has obvious advantages in pharmacological activity compared with other AR antagonists,so it is expected to become the best-in-class among the second-generation new AR antagonists.
16
2016-12
Dr.Youzhi Tong: There Was No Traffic Jam on Xinghu Street in 2009
At the beginning of 2010 when Suzhou Kintor Pharmaceuticals,Inc.("Suzhou Kintor") officially started operation,Dr.Tong's entrepreneurship officially started.By then,he was already middle-aged.
28
2016-11
TOT Biopharm Signed a Production Cooperation Agreement with Suzhou Kintor
TOT Biopharm Co.,Ltd.also located in Suzhou Industrial Park,Jiangsu Province,and Suzhou Kintor Pharmaceuticals,Inc.("Suzhou Kintor") announced that the two parties have signed a drug research and production commissioning contract.
02
2015-12
The List of 10th Anniversary of China's Top 50 Most Valuable Enterprises to Invest in 2015
The selection of China’s top 50 most valuable investment enterprises was initiated by Zero2IPO Group.It is the first annual selection event focusing on high-growth enterprises in the investment community.
17
2015-07
Recently, a new-generation AR antagonist, proxalutamide, independently developed by Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") receives initiation funding for special project of significant novel drugs development in "13th Five-Year plan".
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn